The clinical trial with the medication Jusvinza, developed by the Centre for Genetic Engineering and Biotechnology (CIGB) for the treatment of residual polyarthritis in patients convalescing from chikungunya, has begun in the Cuban province of Matanzas.

Taking place at the Comandante Faustino Pérez Clinical-Surgical-Teaching Hospital in this western territory of Cuba, the research has among its objectives the evaluation of the drug’s efficacy in reducing joint pain and inflammation.

According to reports from the website www.radio26.cu, the study includes persons who suffered from chikungunya and maintain joint symptoms for more than three months, who were selected aged 19 to 80 and under specific criteria to guarantee greater effectiveness in the trial’s results.

The treatment with Jusvinza consists of nine subcutaneous doses distributed over six weeks; in the first week three consecutive doses are applied; in the second, two doses, and from the third to the sixth, one dose weekly, explained Yudisay Reyes, an Oncology specialist and member of the CIGB Clinical Research Group.

To carry out the scheme, this can be done on an outpatient or inpatient basis, depending on the patient’s clinical situation and their place of residence, especially in the case of those living far from the Faustino Pérez Hospital, she said.

The press outlet specifies that the trial involves 120 patients divided into two groups of 60: one that will receive Jusvinza alongside conventional treatment and another that will continue solely with the usual therapy.